Retrieve available abstracts of 59 articles: HTML format
Single Articles
May 2025
KANTARJIAN H, Jain N, Litzow MR, Luger SM, et al The evolving therapeutic revolution in adult acute lymphoblastic leukemia.
Cancer. 2025;131:e35872. PubMedAbstract available
ATALLAH E, Lipton JH Has the time for treatment-free remission in Philadelphia chromosome-positive
acute lymphoblastic leukemia arrived?
Cancer. 2025;131:e35880. PubMed
WINESTONE LE, Yang J, Banerjee T, Sangaramoorthy M, et al Impact of neighborhood archetypes on overall mortality among young patients with
acute leukemia in California.
Cancer. 2025;131:e35863. PubMedAbstract available
April 2025
KANTARJIAN H, Zhai Y, Oehler VG, Jamy O, et al Olverembatinib in chronic myeloid leukemia-Review of historical development,
current status, and future research.
Cancer. 2025;131:e35832. PubMedAbstract available
THAKUR RK, Wang ES Top advances of the year: Acute myeloid leukemia.
Cancer. 2025;131:e35834. PubMed
GOULART H, Kantarjian H, Borthakur G, Daver N, et al Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or
refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.
Cancer. 2025;131:e35840. PubMedAbstract available
PETERS DT, Zeidner JF A second look at the status quo for secondary acute myeloid leukemia after
hypomethylating agents.
Cancer. 2025;131:e35838. PubMed
LEBER B, Ruiz MT, Elgendy H, Pettersson F, et al Real-world treatment patterns and outcomes with oral azacitidine maintenance
therapy in patients with acute myeloid leukemia.
Cancer. 2025;131:e35845. PubMedAbstract available
KHOURI MR, Wang B, Pearson LK, Gillis-Smith AJ, et al Characteristics and clinical outcomes of patients with myeloid malignancies and
cohesin mutations.
Cancer. 2025;131:e35846. PubMedAbstract available
SENAPATI J, Kadia TM, Daver NG, DiNardo CD, et al Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges.
Cancer. 2025;131:e35806. PubMedAbstract available
PAPAYANNIDIS C, Petracci E, Zappasodi P, Fracchiolla N, et al INO-CD22: A multicenter, real-world study of inotuzumab ozogamicin safety and
effectiveness in adult patients with relapsed/refractory acute lymphoblastic
leukemia.
Cancer. 2025;131:e35820. PubMedAbstract available
NANNI J, Azzali I, Papayannidis C, Mule A, et al Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated
AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard
chemotherapy in the real-life setting.
Cancer. 2025;131:e35824. PubMedAbstract available
March 2025
Erratum to "Incorporation of alemtuzumab into frontline therapy of adult acute
lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance),
a phase 1/2 study".
Cancer. 2025;131:e35803. PubMed
BAZINET A, Bataller A, Kadia T, Daver N, et al A retrospective study of outcomes across time and treatment regimens in newly
diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia.
Cancer. 2025;131:e35813. PubMedAbstract available
KUGLER E, Kantarjian H, Jabbour E, Khaire N, et al Treatment-free remission in nontransplanted patients with Philadelphia
chromosome-positive acute lymphoblastic leukemia.
Cancer. 2025;131:e35773. PubMedAbstract available
BROWN JC, Ma C, Shi Q, Saltz LB, et al The association of physical activity with survival in colon cancer versus a
matched general population: Data from Cancer and Leukemia Group B 89803 and 80702
(Alliance).
Cancer. 2025;131:e35727. PubMedAbstract available
February 2025
LUSKIN MR, Yin J, Lozanski G, Curran E, et al Results of Cancer and Leukemia Group B 10102 (Alliance), a Phase 1/2 Study.
Cancer. 2025;131:e35750. PubMedAbstract available
GYAN E, Minden MD, Kubo K, Rambaldi A, et al Maintenance therapy with the FMS-like tyrosine kinase 3 inhibitor gilteritinib in
patients with FMS-like tyrosine kinase 3-internal tandem duplication acute
myeloid leukemia: A phase 2 study.
Cancer. 2025;131:e35746. PubMedAbstract available
ESKAZAN AE Patient-reported outcomes in Chinese patients with chronic myeloid leukemia
receiving olverembatinib: Quality of life matters!
Cancer. 2025;131:e35737. PubMed
January 2025
WANG L, Chen Y, Zang M, Zhou J, et al Molecular measurable residual disease before transplantation independently
predicts survival and relapse risk in adult lysine methyltransferase
2a-rearranged acute myeloid leukemia.
Cancer. 2025;131:e35717. PubMedAbstract available
LLORET-MADRID P, Boluda B, Martinez-Lopez J, Bergua J, et al Treatment patterns and outcomes in secondary acute myeloid leukemia arising after
hypomethylating agents: PETHEMA registry study.
Cancer. 2025;131:e35696. PubMedAbstract available
SASAKI K Favorable transplantation outcome of patients with de novo chronic myeloid
leukemia in blast phase (lymphoid and myeloid).
Cancer. 2025;131:e35704. PubMed
ARGUELLO-TOMAS M, Mozas P, Albiol N, Lopez-Esteban M, et al Risk scores predicting disease progression in early-stage chronic lymphocytic
leukemia: Comparative analysis and usefulness of IGHV subset #2 to improve their
accuracy.
Cancer. 2025;131:e35552. PubMedAbstract available
November 2024
YU L, Li W, Xu N, Liu X, et al Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant
chronic myeloid leukemia receiving olverembatinib therapy.
Cancer. 2024 Nov 26. doi: 10.1002/cncr.35652. PubMedAbstract available
JEN WY, Marvin-Peek J, Kantarjian HM, Alvarado Y, et al Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic
trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
Cancer. 2024 Nov 25. doi: 10.1002/cncr.35662. PubMedAbstract available
ZHANG C, Gu R, Wang H, Zhou C, et al Risk stratification in the clinical application of minimal residual disease
assessment in acute myeloid leukemia.
Cancer. 2024 Nov 10. doi: 10.1002/cncr.35641. PubMedAbstract available
OKADA Y, Tachi N, Shimazu Y, Murata M, et al Comparing de novo chronic myeloid leukemia in blastic phase with Philadelphia
chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic
cell transplantation.
Cancer. 2024 Nov 4. doi: 10.1002/cncr.35627. PubMedAbstract available
NIERENGARTEN MB Blinatumomab approved as consolidation therapy for MRD-negative B-cell precursor
acute lymphoblastic leukemia.
Cancer. 2024;130:3622. PubMed
NIERENGARTEN MB New predictive model for treatment failure in chronic myeloid leukemia.
Cancer. 2024;130:3621. PubMed
HOANG TT, Rathod RA, Rosales O, Castellanos MI, et al Residential proximity to oil and gas developments and childhood cancer survival.
Cancer. 2024;130:3724-3733. PubMedAbstract available
October 2024
RODRIGUEZ-ARBOLI E, Rodriguez-Veiga R, Soria-Saldise E, Bergua JM, et al A phase 2, multicenter, clinical trial of CPX-351 in older patients with
secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX.
Cancer. 2024 Oct 30. doi: 10.1002/cncr.35618. PubMedAbstract available
KONDO T, Matsuki E, Takaku T, Watanabe N, et al Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of
tyrosine kinase inhibitors.
Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611. PubMedAbstract available
NIERENGARTEN MB Durable efficacy with fixed-duration BTKi and venetoclax for CLL.
Cancer. 2024;130:3237. PubMed
September 2024
LI Z, Zhang X, Zhao Y, Lu L, et al Imatinib dose reduction after major molecular response in chronic-phase chronic
myeloid leukemia.
Cancer. 2024 Sep 21. doi: 10.1002/cncr.35565. PubMedAbstract available
August 2024
ZHANG X, Wang Y, Tian X, Sun L, et al Delineation of features, responses, outcomes, and prognostic factors in pediatric
PDGFRB-positive acute lymphoblastic leukemia patients: A retrospective
multicenter study.
Cancer. 2024 Aug 13. doi: 10.1002/cncr.35481. PubMedAbstract available
KANTARJIAN HM, Boissel N, Papayannidis C, Luskin MR, et al Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current
status, and future directions.
Cancer. 2024 Aug 2. doi: 10.1002/cncr.35505. PubMedAbstract available
July 2024
JEN WY, Konopleva M, Pemmaraju N Tagraxofusp, a first-in-class CD123-targeted agent: Five-year postapproval
comprehensive review of the literature.
Cancer. 2024;130:2260-2271. PubMedAbstract available
June 2024
LABRADOR J, Martinez-Cuadron D, Boluda B, Serrano J, et al Evolving patterns and clinical outcome of genetic studies performed at diagnosis
in acute myeloid leukemia patients: Real life data from the PETHEMA Registry.
Cancer. 2024 Jun 19. doi: 10.1002/cncr.35431. PubMedAbstract available
May 2024
SENAPATI J, Kantarjian HM, Bazinet A, Reville P, et al Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older
patients with acute myeloid leukemia compares favorably with intensive
chemotherapy among patients undergoing allogeneic stem cell transplantation.
Cancer. 2024 May 29. doi: 10.1002/cncr.35388. PubMedAbstract available
HADDAD FG, Sasaki K, Nasr L, Short NJ, et al Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic
phase.
Cancer. 2024 May 28. doi: 10.1002/cncr.35384. PubMedAbstract available
BAZARBACHI AH, Labopin M, Raiola AM, Blaise D, et al Posttransplant cyclophosphamide versus anti-thymocyte globulin versus combination
for graft-versus-host disease prevention in haploidentical transplantation for
adult acute myeloid leukemia: A report from the European Society for Blood and
Marrow Tran
Cancer. 2024 May 17. doi: 10.1002/cncr.35365. PubMedAbstract available
April 2024
JABBOUR E, Haddad FG, Sasaki K, Carter BZ, et al Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic
myeloid leukemia.
Cancer. 2024 Apr 9. doi: 10.1002/cncr.35317. PubMedAbstract available
LOKE J, Labopin M, Craddock C, Socie G, et al Prognostic impact of number of induction courses to attain complete remission in
patients with acute myeloid leukemia transplanted with either a matched sibling
or human leucocyte antigen 10/10 or 9/10 unrelated donor: An Acute Leukemia
Working Party
Cancer. 2024 Apr 6. doi: 10.1002/cncr.35308. PubMedAbstract available
WANG X, Zhang B, Zhang Q, Zhou H, et al Impact of tocilizumab on anti-CD19 chimeric antigen receptor T-cell therapy in
B-cell acute lymphoblastic leukemia.
Cancer. 2024 Apr 5. doi: 10.1002/cncr.35316. PubMedAbstract available
March 2024
DUFFY C, Hunger SP, Bhakta N, Denburg AE, et al Curing pediatric cancer: A global view. Examples from acute lymphoblastic
leukemia.
Cancer. 2024 Mar 29. doi: 10.1002/cncr.35290. PubMed
HUANG R, He H, Xu X, Lin X, et al Venetoclax plus a hypomethylating agent versus cytarabine, aclarubicin, and
granulocyte colony-stimulating factor chemotherapy as a first-line therapy for
newly diagnosed acute myeloid leukemia: A propensity score-matched analysis.
Cancer. 2024 Mar 12. doi: 10.1002/cncr.35278. PubMedAbstract available
ROSENBERG SM, McCue S, He J, Lafky JM, et al Alliance A151945: Accrual and characteristics of adolescent and young adult
patients in Alliance trials from 2000 to 2017.
Cancer. 2024;130:750-769. PubMedAbstract available
February 2024
DINH A, Savoy JM, Kontoyiannis DP, Takahashi K, et al Ivosidenib significantly reduces triazole levels in patients with acute myeloid
leukemia and myelodysplastic syndrome.
Cancer. 2024 Feb 10. doi: 10.1002/cncr.35251. PubMedAbstract available
GUAN F, Yang L, Chen Y, Shi J, et al Comparison of long-term outcomes between imatinib and dasatinib prophylaxis after
allogeneic stem cell transplantation in patients with Philadelphia-positive acute
lymphoblastic leukemia: A multicenter retrospective study.
Cancer. 2024 Feb 5. doi: 10.1002/cncr.35232. PubMedAbstract available
January 2024
SEDETA E, Jemal A, Nisotel L, Sung H, et al Survival difference between secondary and de novo acute myeloid leukemia by age,
antecedent cancer types, and chemotherapy receipt.
Cancer. 2024 Jan 20. doi: 10.1002/cncr.35214. PubMedAbstract available
December 2023
PALANDRI F, Palumbo GA, Benevolo G, Iurlo A, et al Incidence of blast phase in myelofibrosis patients according to anemia severity
at ruxolitinib start and during therapy.
Cancer. 2023 Dec 28. doi: 10.1002/cncr.35156. PubMedAbstract available
November 2023
YANG X, Yang L, Luo A, Liu S, et al IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic
leukemia in children.
Cancer. 2023 Nov 29. doi: 10.1002/cncr.35129. PubMedAbstract available
RUIZ J, Li Y, Cao L, Huang YV, et al Association of the social disorganization index with time to first septic shock
event in children with acute myeloid leukemia.
Cancer. 2023 Nov 20. doi: 10.1002/cncr.35109. PubMedAbstract available
NIERENGARTEN MB New potential therapy for relapsed chronic lymphocytic leukemia and small
lymphocytic lymphoma.
Cancer. 2023;129:3356. PubMed
October 2023
PULLARKAT V, Chen LS, Palmer J, Zhang J, et al A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid
leukemia: An evaluation of safety and pharmacokinetics.
Cancer. 2023 Oct 28. doi: 10.1002/cncr.35077. PubMedAbstract available
GUPTA DG, Varma N, Abdulkadir SA, Sreedharanunni S, et al A surrogate molecular approach for the detection of Philadelphia chromosome-like
B-acute lymphoblastic leukemia.
Cancer. 2023 Oct 11. doi: 10.1002/cncr.35051. PubMedAbstract available
EFFICACE F, Cottone F, Yanez B, Kota V, et al Patient-reported symptom monitoring and adherence to therapy in patients with
newly diagnosed chronic myeloid leukemia.
Cancer. 2023 Oct 6. doi: 10.1002/cncr.35021. PubMedAbstract available
September 2023
SASAKI K, Haddad FG, Short NJ, Jain N, et al Outcome of Philadelphia chromosome-positive chronic myeloid leukemia in the
United States since the introduction of imatinib therapy-The Surveillance,
Epidemiology, and End Results database, 2000-2019.
Cancer. 2023 Sep 28. doi: 10.1002/cncr.35038. PubMedAbstract available
GIEBEL S, Labopin M, Salmenniemi U, Socie G, et al Posttransplant cyclophosphamide versus antithymocyte globulin in patients with
acute lymphoblastic leukemia treated with allogeneic hematopoietic cell
transplantation from matched unrelated donors. A study from the Acute Leukemia
Working Party of the
Cancer. 2023 Sep 1. doi: 10.1002/cncr.35004. PubMedAbstract available